Nobel Biocare (NVST): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Envista Holdings Corp (NVST)

The market expects Envista Holdings (NVST) under new management to increase margins, as evidenced by fluctuations in the P/S multiple, where the parameter value is 1.30. Global equipment exports are constrained by geopolitics and disruptions in Asia. Consumables ensure revenue stability, although demand for implants remains dependent on economic conditions. This chart's price action helps balance the risks of a drawdown against the potential for business value growth.

Price-to-Revenue Ratio: Envista (NVST) for 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for Envista (NVST)

Summary company analytics:Envista Holdings Corporation
Mass-produced product of envistaco.com

Stable demand for Envista Holdings (NVST) dental equipment, regardless of geopolitics, makes the company's revenue a predictable foundation for valuation. By analyzing price-to-sales dynamics, an investor determines the market value of a single dollar of sales, which helps identify if the asset is overbought relative to its actual income and avoids investing in a speculative bubble during an anomalous surge in the multiple.

Competitors of Envista Holdings

Market Cap to Sales Volume ISRG|Danaher Corporation - Market Cap to Revenue|P/S Multiple Becton Dickinson & Company BDX|STE - Price-to-Revenue Ratio|West Pharmaceutical Services (WST) - Market Cap to Revenue|BAX: P/S Multiple|Market Cap to Revenue Masimo|STVN (stevanatogroup.com) - P/S Multiple|Market Cap to Revenue Ratio TFX (Teleflex Incorporated)|Price-to-Revenue Ratio Merit Medical (MMSI)|ICU Medical - Market Cap to Revenue Ratio|DENTSPLY SIRONA Inc. - Market Cap to Revenue|Market Cap to Sales Volume LMAT (LeMaitre Vascular Inc)|ATRC - Price-to-Revenue Ratio|Price-to-Revenue Coefficient STAAR Surgical Co STAA|NAGE: P/S Multiple|Price-to-Sales Ratio ZIMV (ZimVie Inc.)|Price-to-Revenue Ratio AngioDynamics Corp|Price to Sales Cerus Corp. CERS|Price-to-Revenue Ratio Teknova (TKNO)|Monogram Orthopedics Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Sharps Technology, Inc. STSS|P/S Multiple InfuSystem Holdings INFU|UTMD: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KRMD (KORU Medical)|NYXH: P/S Multiple|MBOT (Microbot Medical, Inc) - Price-to-Revenue Ratio|Market Cap to Revenue PDEX|ZTEK: Market Capitalization-to-Revenue Ratio|P/S Multiple ELUT|Milestone Scientific Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio NEXGEL, Inc. NXGL|Retractable Tech - Price-to-Revenue Ratio|harvardbioscience.com - P/S Multiple|FEMY (Femasys Inc.) - Market Cap to Revenue Ratio|MHUA: P/S Multiple|Predictive Oncology Corp - Market Capitalization-to-Revenue Ratio|CJMB (Callan JMB) - P/S Multiple|Price to Sales Atrion Corporation Inc. ATRI|P/S Multiple NURO